TrialCancer science2014

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.

Michinori Ogura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.